Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
AssigneeSherbrooke University
InventorAlain Cadieux
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of calcitonin gene-related peptide (CGRP) in the prevention and alleviation of asthmatic symptoms. In contrast to other therapeutic agents now in use, CGRP combines both bronchoprotector and anti-inflammatory properties. Furthermore, it prevents both early and late phase bronchial responses associated with an asthma attack and its effective dose is small enough that undesirable haemodynamic side effects are not present.
Claims13
A method of reducing a stimulus-induced airway response selected from the group consisting of airway constriction, bronchospasm, airway hyperreactivity, eosinophil accumulation in bronchial walls, an increase in airway resistance, or combinations thereof, said method comprising:
- administering by inhalation to a subject at risk of experiencing said stimulus-induced airway response a therapeutically effective amount of an agent selected from the group consisting of:
- (a) human calcitonin gene-related peptide (human CGRP);
- (b) rat CGRP;
- (c) the diacetoamidomethyl cysteine form of (a);
- and
- (d) the diacetoamidomethyl cysteine form of (b);
- wherein said agent is administered prior to said airway response and wherein said method results in no or substantially no haemodynamic side effects.
Dependencies are inferred from the claim text.